--Amgen today announced new data from a real-world study of nearly half of a million postmenopausal women with osteoporosis in the U.S. medicare program showing Prolia ® injection reduced fracture ...

Original Medicare (Part A and Part B), Part D, and Medicare Advantage typically offer coverage for the osteoporosis drug Prolia. However, individuals must meet certain requirements for Part B coverage ...

Prolia (denosumab) is a medication for osteoporosis. A healthcare professional administers Prolia via injection under the skin every 6 months. Medicare covers Prolia for beneficiaries. Since a ...

(RTTNews) - Alvotech (ALVO) announced that the European Commission has approved AVT03, a biosimilar to Amgen's Prolia and Xgeva for use across Europe. Prolia is indicated to treat osteoporosis and ...

Sandoz has obtained the Food and Drug Administration’s clearance for Wyost (denosumab-bbdz) and Jubbonti (denosumab-bbdz), the only FDA-approved denosumab biosimilars, to treat all indications of ...

Dr. Reddy’s and Alvotech have entered into a license and supply agreement for the commercialization of AVT03, Alvotech’s biosimilar candidate to Prolia and Xgeva (denosumab). The collaboration ...

LOS ANGELES, March 23 (Reuters) - Amgen Inc's Prolia bone drug continues to improve bone mineral density in post-menopausal women treated with the drug for up to five years, according to new data ...

The Ministry of Food and Drug Safety (MFDS) approved South Korea’s first denosumab (Prolia/Xgeva) biosimilars, developed by Celltrion Inc. under the brand names of Stoboclo/Osenvelt (CT-P41) for ...

Update 11:25am on April 30: Adds Amgen, Sandoz comment. A preliminary injunction hearing in an Amgen (NASDAQ:AMGN) patent lawsuit against Sandoz (OTCQX:SDZNY) over potential generic entry of its ...